Antibody Drug Conjugates (ADCs) are a promising class of targeted cancer therapies that combine the specificity of monoclonal antibodies with the cytotoxic activity of chemotherapeutic agents. ADCs have the potential to improve cancer treatment by selectively targeting cancer cells, reducing toxicity to healthy tissues, and improving therapeutic outcomes. In this article, we will discuss the mechanism of action of ADCs, their development, and their potential applications in cancer therapy.
Published Date: 2023-02-27; Received Date: 2023-02-03
